

<b>Form PTO-1449</b> <b>INFORMATION DISCLOSURE CITATION</b> <b>IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>	Docket Number 54587200100	Application Number Not Yet Assigned
	Applicant Gustavo A. MOVIGLIA	
	Filing Date Concurrently Herewith	Group Art Unit Not Yet Assigned
	Mailing Date March 15, 2004	

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
/C.Q./	1.	04/03/2001	6,210,662	Laus et al.			
↓	2.	04/04/1998	5,597,312	Murphy et al.			
↓	3.	04/11/2002	US 2002/0041868 A1	Nicolette et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
/C.Q./	4.	08/16/2001	01/59073	WO			
↓	5.	10/22/1998	98/46785	WO			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
/C.Q./	6.	Gong, J. et al. (2000). "Selection and Characterization of MUC1-Specific CD8 <sup>+</sup> T Cells from MUC1 Transgenic Mice Immunized with Dendritic-Carcinoma Fusion Cells." <i>Immunology</i> , 101:316-324.
↓	7.	Li, J. et al. (2001). "Purified Hybrid Cells from Dendritic Cell and Tumor Cell Fusions are Superior Activators of Antitumor Immunity." <i>Cancer Immunol Immunother</i> 50: 456-462.
↓	8.	Tanaka, Y. et al. (2001). "Vaccination with Allogenic Dendritic Cells Fused to Carcinoma Cells Induces Antitumor Immunity in MUC1 Transgenic Mice." <i>Clinical Immunology</i> Vol. 101, No. 2, pp. 192-200.
↓	9.	Guo, Y. et al. (1994). "Effective Tumor Vaccine Generated by Fusion of Hepatoma Cells with Activated B Cells." <i>Science</i> , 263: 518-520.
↓	10.	Valone F. H. et al. (2001). "Dendritic Cell-Based Treatment of Cancer: Closing in on a Cellular Therapy." <i>The Cancer Journal</i> , 7: S53-S61.
↓	11.	Moviglia, G. A. (1996). "Development of Tumor B-Cell Lymphocyte Hybridoma (TBH) Autovaccination. Results of a Phase I-II Clinical Trial." <i>Transfus. Sci.</i> , Vol 17, No. 4, pp. 643-649.
↓	12.	Hersey P. et al. (2004). "Phase I/II Study of Treatment with Dendritic Cell Vaccines in Patients with Disseminated Melanoma." <i>Cancer Immunol Immunother</i> , 53: 125-134.

EXAMINER: /Celine Qian/

DATE CONSIDERED: 06/07/2007

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 54587200100	Application Number Not Yet Assigned
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Applicant Gustavo A. MOVIGLIA	
		Filing Date Concurrently Herewith	Group Art Unit Not Yet Assigned
		Mailing Date March 15, 2004	


/C.Q./	13.	Moviglia G. A. et al. (2000). "Dendritic Cells Preparation for Cancer Treatment." <i>Journal of Clinical Apheresis</i> 15:187. Abstracts of the 21 <sup>st</sup> Annual Meeting of the American Society for Apheresis.
	14.	Moviglia, G. A. (04/17/02). "Dendritic Cells Preparation for Cancer Treatment." 26 pages. Located at <a href="http://www.santojanni.org.ar/hemoterapia/Dcl/">http://www.santojanni.org.ar/hemoterapia/Dcl/</a> printed on 3/12/04.
	15.	Gong, J. et al. (1997). "Induction of Antitumor Activity by Immunization with Fusions of Dendritic and Carcinoma Cells." <i>Nature Medicine</i> , Vol. 3, No. 5, pp. 558-561.
	16.	Grabbe, S. et al. (1995). "Dendritic Cells as Initiators of Tumor Immune Responses: A Possible Strategy for Tumor Immunotherapy." <i>Immunology Today</i> , Vol. 16, No. 3, pp. 117-121.
	17.	Timmerman, J. & Levy, R. (1999). Dendritic Cell Vaccines for Cancer Immunotherapy." <i>Annu. Rev. Med.</i> 50: 507-529.
	18.	Qin, Z. et al. (1998). "B Cells Inhibit Induction of T Cell-Dependent Tumor Immunity." <i>Nature Medicine</i> , Vol. 4, No.5, pp. 627-630.
	19.	Wu, S. (1998). "Treatment of Hepatocellular Carcinoma with the Cellular Tumor Vaccines Generated by <i>In-Vitro</i> Modification of Tumor Cells with Non Gene Transfer Approaches." <i>Gene Therapy of Cancer</i> , pp. 283-293.
	20.	Gong, J. et al. (2000). Fusions of Human Ovarian Cells with Autologous or Allogenic Dendritic Cells Induce Antitumor Immunity." <i>The Journal of Immunology</i> , 165: 1705-1711.
	21.	Celluzzi, C. M. & Falo, L. D. Jr. (1998). "Cutting Edge: Physical Edge: Physical Interaction between Dendritic Cells and Tumor Cells Results in an Immunogen that Induces Protective and Therapeutic Tumor Rejection." <i>The Journal of Immunology</i> , 160: 3081-3085.
	22.	Surman, D. R. et al. (2000). "Cutting Edge: CD4 <sup>+</sup> T Cell Control of CD8 <sup>+</sup> T Cell Reactivity to a Model Tumor Antigen." <i>The Journal of Immunology</i> , 164: 562-565.
	23.	Wang, J. et al. (1998). "Eliciting T Cell Immunity Against Poorly Immunogenic Tumors by Immunization with Dendritic Cell-Tumor Fusion Vaccines." <i>The Journal of Immunology</i> , 161: 5516-5524.
	24.	Strome, S. E. et al. (2002). Strategies for Antigen Loading of Dendritic Cells to Enhance the Antitumor Immune Response." <i>Cancer Research</i> , 62: 1884-1889.
	25.	Morse, M. A. et al. (1999). "Migration of Human Dendritic Cells after Injection in Patients with Metastatic Malignancies." <i>Cancer Research</i> , 59: 56-58.
	26.	Gong, J. et al. (2001). "Immunization Against Murine Multiple Myeloma with Fusions of Dendritic and Plasmacytoma Cells is Potentiated by Interleukin 12." <i>Immunology</i> , Vol. 99, No. 7, pp. 2512-2517.
	27.	Gong, J. et al. (2000). "Activation of Antitumor Cytotoxic T Lymphocytes by Fusions of Human Dendritic Cells and Breast Carcinoma Cells." <i>Immunology</i> , Vol. 97, No. 6, pp. 2715-2718.
✓	28.	Homma, S. et al. (2001). "Preventive Antitumor Activity Against Hepatocellular Carcinoma (HCC) Induced by Immunization with Fusions of Dendritic Cells and HCC Cells in Mice." 36: 764-771.

EXAMINER: Celine Qian	DATE CONSIDERED:
-----------------------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

sf- 1662570PTO/SB/ 08 (2-92) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



ALTERNATIVE TO PTO/SB/08a/b (07-05)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/802,097
				Filing Date	March 15, 2004
				First Named Inventor	Gustavo A. MOVIGLIA
				Art Unit	1632
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	545872000100

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T <sup>6</sup>

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
IC.Q	1.	European Search Report mailed August 5, 2005, for European patent application no. 05101982.6 filed March 14, 2005, 2 pages	
IC.Q	2.	BOCCHIA, Monica et al. (2000) "Antitumor Vaccination: Where We Stand," Hematologica, 85: 1172-1206	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Celine Qian	<small>Digitally signed by Celine Qian DN: cn=Celine Qian, o=US, ou=USPTO, ou=1632, email=cqian@uspto.gov Date: 2007.08.07 13:41:06 -0400</small>	Date Considered	
-----------------------	-------------	---	--------------------	--

sf- 1988227